# SUBJECT INDEX


A

Abboud, H. E., 297–307
ACE
  See Angiotensin-converting enzyme
Acetylcholine
  nitric oxide formation and, 684
Acetylcholine receptor
  See Nicotinic acetylcholine receptor
N-Acetylglucosamine
  salivary mucin biosynthesis and, 553
*Acholeplasma laidlawii*
  membrane lipids
    temperature and, 21–22
*Acholeplasma laidlawii* B
  membrane fluidity
    temperature and, 24–25
Acid(s)
  hydrophobic lipid barriers, 566–67
Acidemia
  hypoxic pulmonary vasoconstriction and, 128
  pulmonary vascular resistance and, 120
Acidosis
  hypoxic pulmonary vasoconstriction and, 128
Acinar cells
  mucus, 547
  serous, 547
Aconitase
  nitric oxide and, 690, 752
ACTH
  nitric oxide synthase and, 694
Actin
  endothelin-1 and, 182
Actin polymerization
  chemoattractant receptors and, 837
Action potential
  ionic theory, 3
  muscle
    membrane voltage-dependent sodium channels and, 355
  sodium pumps and, 79
Activin
  assay development, 227–28
  binding proteins, 234–35
  binding sites in ovary, 230–31
  bioassays, 222
  deficiency
    animal models, 234
  embryonic expression, 236–37
  follicular maturation and, 233–34
  identification, 220
  menstrual cycle and, 227–29
  mRNA and protein localization in ovary, 229–30
  outside reproductive axis, 221–22
  pituitary and ovarian response, 231–32
  pregnancy and, 227–29
  radioimmunoassay, 227
  receptors, 235–36
  subunit characterization, 220
Activity metabolism
  in reptiles, birds, mammals, 74–75
Acute Infarction Ramipril Efficacy (AIRE) study, 817–18
Adaptation
  homeophasic, 32–33
  homeoviscous, 19–37
    membrane remodeling and, 23–31
  thermal
    biological membranes and, 19–37
    membrane remodeling and, 22–23
    paralogous homologues and, 53–54
    protein function and, 48–50
    protein structural stability and, 46–48
Adaptive cytoprotection, 578
Adenosine
  hypoxic coronary vasodilation and, 774–75
  ischemic preconditioning and, 322–24
Adenosine triphosphate
  See ATP
Adenylate cyclase activators
  mucin secretion and, 595–96
Adenylyl cyclase
  cardiac chloride channel and, 391
  endothelin and, 174
Adhesion molecules
  inflammatory cytokines and, 830–31
  inflammatory response and, 108
Adipose tissue
  brown
    nonshivering thermogenesis and, 70
ADP ribosyl cyclase
  nitric oxide and, 689–90
Adrenal glands
  angiotensin II receptors, 284
$\alpha_2$-Adrenoceptor
  nitrergic nerve terminals and, 665
Adriamycin
  nephrotic syndrome and, 255, 274
  progressive glomerular sclerosis and, 273–74
  reactive oxygen metabolites and, 248
Aerobiosis, 77
AIDS nephropathy
  glomerular sclerosis and, 272
Airway tone
  See Pulmonary airway tone
Aldosterone
  cellular membrane and, 6
  synthesis and secretion
    angiotensin II and, 284–85
Alimentation
  salivary mucins and, 555
Allograft rejection
  intercellular adhesion molecule-1 and, 842
Allopurinol
  PAN-induced nephrotic syndrome and, 254
Allozymes
  thermal stability, 52–53
Alpha-1 antitrypsin
  surfactant subtype conversion and, 140
*Alticus kirkii*
  lens crystallins
    temperature of 50% loss of structure, 47
Alveolar capillay network, 99
Alveolar epithelial type II cells
  extracellular surfactant and, 135
  phospholipid remodeling enzymes, 570
  surfactant convertase and, 143–44
Alveolar macrophages, 108
Amines
  reactions with nitric oxide, 748
Amino acids
  heme-interacting
    nitric oxide synthase and, 728

# SUBJECT INDEX


A

Abboud, H. E., 297–307
ACE
  See Angiotensin-converting enzyme
Acetylcholine
  nitric oxide formation and, 684
Acetylcholine receptor
  See Nicotinic acetylcholine receptor
N-Acetylglucosamine
  salivary mucin biosynthesis and, 553
*Acholeplasma laidlawii*
  membrane lipids
    temperature and, 21–22
*Acholeplasma laidlawii* B
  membrane fluidity
    temperature and, 24–25
Acid(s)
  hydrophobic lipid barriers, 566–67
Acidemia
  hypoxic pulmonary vasoconstriction and, 128
  pulmonary vascular resistance and, 120
Acidosis
  hypoxic pulmonary vasoconstriction and, 128
Acinar cells
  mucus, 547
  serous, 547
Aconitase
  nitric oxide and, 690, 752
ACTH
  nitric oxide synthase and, 694
Actin
  endothelin-1 and, 182
Actin polymerization
  chemoattractant receptors and, 837
Action potential
  ionic theory, 3
  muscle
    membrane voltage-dependent sodium channels and, 355
  sodium pumps and, 79
Activin
  assay development, 227–28
  binding proteins, 234–35
  binding sites in ovary, 230–31
  bioassays, 222
  deficiency
    animal models, 234
  embryonic expression, 236–37
  follicular maturation and, 233–34
  identification, 220
  menstrual cycle and, 227–29
  mRNA and protein localization in ovary, 229–30
  outside reproductive axis, 221–22
  pituitary and ovarian response, 231–32
  pregnancy and, 227–29
  radioimmunoassay, 227
  receptors, 235–36
  subunit characterization, 220
Activity metabolism
  in reptiles, birds, mammals, 74–75
Acute Infarction Ramipril Efficacy (AIRE) study, 817–18
Adaptation
  homeophasic, 32–33
  homeoviscous, 19–37
    membrane remodeling and, 23–31
  thermal
    biological membranes and, 19–37
    membrane remodeling and, 22–23
    paralogous homologues and, 53–54
    protein function and, 48–50
    protein structural stability and, 46–48
Adaptive cytoprotection, 578
Adenosine
  hypoxic coronary vasodilation and, 774–75
  ischemic preconditioning and, 322–24
Adenosine triphosphate
  See ATP
Adenylate cyclase activators
  mucin secretion and, 595–96
Adenylyl cyclase
  cardiac chloride channel and, 391
  endothelin and, 174
Adhesion molecules
  inflammatory cytokines and, 830–31
  inflammatory response and, 108
Adipose tissue
  brown
    nonshivering thermogenesis and, 70
ADP ribosyl cyclase
  nitric oxide and, 689–90
Adrenal glands
  angiotensin II receptors, 284
$\alpha_2$-Adrenoceptor
  nitrergic nerve terminals and, 665
Adriamycin
  nephrotic syndrome and, 255, 274
  progressive glomerular sclerosis and, 273–74
  reactive oxygen metabolites and, 248
Aerobiosis, 77
AIDS nephropathy
  glomerular sclerosis and, 272
Airway tone
  See Pulmonary airway tone
Aldosterone
  cellular membrane and, 6
  synthesis and secretion
    angiotensin II and, 284–85
Alimentation
  salivary mucins and, 555
Allograft rejection
  intercellular adhesion molecule-1 and, 842
Allopurinol
  PAN-induced nephrotic syndrome and, 254
Allozymes
  thermal stability, 52–53
Alpha-1 antitrypsin
  surfactant subtype conversion and, 140
*Alticus kirkii*
  lens crystallins
    temperature of 50% loss of structure, 47
Alveolar capillay network, 99
Alveolar epithelial type II cells
  extracellular surfactant and, 135
  phospholipid remodeling enzymes, 570
  surfactant convertase and, 143–44
Alveolar macrophages, 108
Amines
  reactions with nitric oxide, 748
Amino acids
  heme-interacting
    nitric oxide synthase and, 728

protein kinase and, 422–24
Avian endothermy, 69–91
evolutionary physiology, 72–82
fossil evidence, 82–83

B

*Bacillus subtilis*
membrane fluidity
temperature and, 25
Bacteria
evolutionary temperature adaptation, 56
hyperthermophilic, 44
Bansil, R., 635–53
Barchi, R. L., 355–80
Basic fibroblast growth factor (bFGF)
C-natriuretic peptide secretion and, 180
transforming growth factor-β and, 287
Basophils
leukocyte chemoattractants and, 835
Becker's disease, 367
bFGF
See Basic fibroblast growth factor
Bicarbonate ions
gastric mucus and, 648
Biglycan
diabetic nephropathy and, 282
Bile salts
mucosal phospholipid metabolism/hydrophobicity and, 574
Biogeographical patterning
temperature and, 45
Biological membranes
thermal adaptation, 19–37
Bipolar cells
cyclic GMP-operated channels, 688
Birds
activity metabolism, 74–75
evolution of endothermy, 69–91
metabolic status, 85–89
oxygen delivery systems, 75–76
temperature set point and resting metabolic rate, 72–73
thermal conductance, 72
Bismuth salts
gastroprotective mechanisms, 578
Blood coagulation
von Willebrand factor and, 637
Blood pressure
nitric oxide and, 771–84
Border, W. A., 279–91
Boulton, C. L., 683–700
Bovine submaxillary mucin-like protein, 623–24
Bradykinin
angiotensin-converting enzyme inhibitors and, 812–13
calcium/calmodulin-dependent protein kinase and, 423
nitric oxide formation and, 684
postnatal pulmonary vascular tone and, 128
pulmonary vascular resistance and, 124–25
Brain
blood flow
nitric oxide and, 699–700
calcium/calmodulin-dependent protein kinase, 427–28
ischemia/reperfusion injury
leukocytes and, 315
Braun, A. P., 417–38
Brefeldin A
mucin synthesis and, 587
Bronchial circulation
leukocyte traffic, 100–11
Bronchiolitis
leukocyte emigration and, 106
Bronchitis
leukocyte emigration and, 106
Bronchoconstriction
nitrogen oxides and, 165
tachykinins and, 157
Brown adipose tissue
nonshivering thermogenesis and, 70
α-Bungarotoxin
nicotinic acetylcholine receptor and, 522, 529

C

Ca1, 610
Calcineurin
interleukin 2 gene expression and, 437
Calcium
cardiac excitation-contraction coupling and, 431
as intracellular second messenger, 417
mucin secretion and, 597–99
nicotinic acetylcholine receptor and, 528, 535–36
nitrergic transmission and, 673
nitric oxide production and, 684
serotonin receptor channel and, 453–54, 463–64
Calcium/calmodulin-dependent protein kinase, 417–38
cardiovascular system and, 431–34
epithelia and, 434–35
gene expression and, 435–37
nervous system and, 427–31
structural and autoregulatory properties, 420–24
substrates, 419–20
Calcium pump
lipid and, 10–11
$Mg^{2+}$ and, 10
phospholamban and, 431–32
Calmodulin
nitric oxide synthase and, 684, 716, 721–22, 739
CaM kinase
See Calcium/calmodulin-dependent protein kinase
Cancer
inhibin and, 232–33
MUC2 and, 617
Canine tracheobronchial mucin, 621
Capillary endothelium
stretch-activated cation channels, 336
Captopril
progressive renal disease and, 286
Carbachol
mucin secretion and, 592, 595
Carbohydrates
leukocyte trafficking and, 831–32
Carcinoma
MUC1 mucin and, 609
Cardenolides, 7
Cardiac excitation-contraction coupling
calcium and, 431
Cardiac glycosides
sodium-potessium pump and, 6–8
Cardiac hypertrophy
renin-angiotensin system and, 285
Cardiac muscle
active metabolic rate and, 78
Cardiac remodeling
clinical studies, 815–21
Cardiovascular system
calcium/calmodulin-dependent protein kinase and, 431–34
Catalase
nitric oxide and, 749
prevention of proteinuria and, 250
reduction of hydrogen peroxide to water and, 256
Catecholamines
calcium/calmodulin-dependent protein kinase and, 429

Cation channels
calcium/calmodulin-dependent protein kinase and, 435
stretch-activated, 334–37
Cations
serotonin receptor channel and, 452–54
CD31, 841–42
CD44, 842
*Cebidichthys violaceous*
lens crystallins
temperature of 50% loss of structure, 47
Cell adhesion proteins
transforming growth factor-β and, 281
Cell volume
stretch-activated cation channels and, 334–35
Central nervous system (CNS)
angiotensin II receptors, 284
C-natriuretic peptide, 180
nitric oxide signaling, 683–700
nitric oxide synthase inhibition and, 777–78
non-NMDA receptors, 508–9
serotonin receptor activation and, 448–49
Cerebellum
C-natriuretic peptide, 180
Cerebral blood flow
nitric oxide and, 699–700
Cerebral infarction
lesions of atherosclerosis and, 791
CF
See Cystic fibrosis
C-fibers
mast cell interactions, 159
neuropeptide synthesis and, 156–57
CFTR
See Cystic fibrosis transmembrane regulator
Chaperones, 58
Chemoattractant(s)
inflammation and, 857
leukocyte trafficking and, 835–37
neutrophil emigration in inflammation and, 844–45
Chemoattractant receptors
functions, 837
Chemokines
leukocyte migration and, 102–3, 835–36
lymphocyte emigration and, 857
Chemotaxis, 835
Cheynes-Stokes respiration, 3
Chloride channels
calcium/calmodulin-dependent protein kinase and, 434–35
cardiac, 387–410
biophysical/pharmacological characterization, 402–6
clinical significance, 408–10
functional role, 408–10
molecular biological characterization, 406–8
nucleoside triphosphates and, 396–401
phosphorylation/dephosphorylation and, 393–96
signal transduction pathways, 390–92
Chlorophyll
thermal denaturation, 27
Cholera toxin
mucin secretion and, 595–96
Cholinergic agonists
mucin secretion and, 594
Choroid plexus
stretch-activated cation channels, 334
Chymotrypsin
light emission from glomeruli and, 248
mucin secretion and, 597
surfactant subtype conversion and, 141
Chymotrypsinogen A
leukocyte adhesion and, 318
Circulatory shock
nitric oxide and, 758–59
Citric acid cycle
nitric oxide and, 690
CNS
See Central nervous system
Cobra venom factor, 108
proteinuria/neutrophil depletion and, 251
Cold-restraint stress
mucosal phospholipid metabolism/hydrophobicity and, 574
Cold shock, 58
Colitis
ulcerative, 597
goblet cells and, 587–88
Collagen
myocardial fibrosis and, 814–15
transforming growth factor-β and, 281
Collecting duct cells
platelet-derived growth factor and, 299
Colquhoun, D., 469–88, 495–513
Compensatory growth
progressive renal disease and, 271–75
Compensatory hypertrophy, 263
Complement
circulating polymorphonuclear leukocytes and, 105–6
oxidative burst and, 247
Complement activation
serine proteases and, 142
Compound exocytosis, 588–92
Concanavalin A
kainate receptor and, 508
Congestive heart failure
angiotensin-converting enzyme inhibition and, 815
CONSENSUS-II, 818
Corneal epithelium
stretch-activated cation channels, 334
Coronary vasodilation
hypoxic
nitric oxide and, 774–75
Corticotropin-releasing hormone
nitric oxide synthase and, 694
Cortisol
hepatic glucose production and, 201–6
*Coryphaenoides armatus*
lens crystallins
temperature of 50% loss of structure, 47
*Coryphaenoides rupestris*
lens crystallins
temperature of 50% loss of structure, 47
COX
See Cyclooxygenase
Crayfish
heat death, 22
Crohn's disease, 597
Crosstalk, 182–84
Cyanobacteria
desaturase mutants
low temperature inhibition of photosynthesis, 29
photosynthetic activity
temperature and, 22
plasma membrane lipids
isothermal catalytic hydrogenation, 27
Cyanotic heart disease
glomerular sclerosis and, 272
Cyclic AMP
glomerular ultrafiltration coefficient and, 252
Cyclic GMP
nitric oxide and, 683, 686–90
Cyclooxygenase (COX)
nitric oxide and, 690, 750
Cyclosporin
endothelial dysfunction and, 781
Cyclothiazide
AMPA receptor and, 508

*Cyprinus carpio*
myosin light chain isoforms
acclimation temperature and, 53
Cysteine
nitrergic transmitter and, 671
Cysteinyl leukotrienes
pulmonary airway tone and, 151–56
Cystic fibrosis (CF), 387, 434
Cystic fibrosis transmembrane regulator (CFTR), 387–410, 434
biophysical/pharmacological characterization, 402–6
clinical significance, 408–10
functional role, 408–10
gating
nucleoside triphosphates and, 396–401
molecular biological characterization, 406–8
regulation
phosphorylation/dephosphorylation and, 393–96
signal transduction pathways, 390–92
Cytisine
neuronal nicotinic acetylcholine receptor and, 533
Cytochalasin
endothelin-1 and, 181
Cytochalasin D
goblet cells and, 591
Cytochrome c
nitric oxide synthase electron transfer and, 719–20
Cytochrome c oxidase
inactivation in mitochondrial membranes
temperature and, 27
Cytochrome P450
nitric oxide synthase and, 722–23
Cytokines
C-natriuretic peptide and, 181
endothelin-1 and, 173
inflammatory
adhesion molecules and, 830–31
kidney disease and, 302
monocyte-specific, 253
Cytoprotection, 576–77
adaptive, 578
Cytoskeleton
mechanosensitive channels and, 347
Cytostasis
nitric oxide-mediated, 753

D

Deferoxamine
anti-GBM antibody disease and, 254
Delayed-type hypersensitivity
intercellular adhesion molecule-1 and, 842
Dephosphorylation
cardiac chloride channel and, 393–96
DF3 antigen, 610
DFP
See Diisopropylfluorophosphate
Diabetes mellitus
endothelium-dependent vasorelaxation and, 178
glomerular sclerosis and, 272
Diabetic nephropathy
angiotensin-converting enzyme inhibitors and, 286, 289–90
end-stage renal failure and, 282
platelet-derived growth factor and, 305
Diamide
nitrergic transmitter and, 670–71
Diazoxide
cardiac chloride channel and, 405
DIDS
cardiac chloride channel and, 404
Digestion
serine proteases and, 142
Dihydrocytochalasin B
goblet cells and, 591
Dihydropyridine receptor, 12
Dihydropyridine receptor gene
hypokalemic periodic paralyis and, 366
Diisopropylfluorophosphate (DFP)
surfactant subtype conversion and, 140
Dimethylthiourea
anti-GBM antibody disease and, 254
Dinosaurs
metabolic status, 85–89
Dipalmitoylphosphatidylcholine (DPPC)
gastric mucosa and, 569–70
Diphenylene iodonium (DPI)
nitric oxide synthase and, 664
1,6-Diphenyl-1,3,5-hexatriene (DPH)
membrane fluidity and, 23
2,3-Diphosphoglycerate (2,3-DPG)
protein thermal stability and, 56
*Dipsosaurus*
endotherm-like fever response, 73
*Dipsosaurus dorsalis*
$A_4$-lactate dehydrogenase
kinetic properties, 48
lens crystallins
temperature of 50% loss of structure, 47
Disulfide bridges
protein thermal stability and, 61
Dithiothreitol
nitrergic transmitter and, 671
Divalent cations
serotonin receptor channel and, 453–54
DNA synthesis
nitric oxide and, 753–54
DNDS
cardiac chloride channel and, 404
Docosahexanoic acid
plasma membrane, 79
Doerschuk, C. M., 97–111
Dopamine
nitric oxide and, 693
serotonin receptor activation and, 449
Dorsal root ganglion
serotonin receptor activation and, 448–49
2,3-DPG
See 2,3-Diphosphoglycerate
DPH
See 1,6-Diphenyl-1,3,5-hexatriene
DPI
See Diphenylene iodonium
DPPC
See Dipalmitoylphosphatidylcholine
Drazen, J. M., 151–65
*Drosophila*
evolutionary temperature adaptation, 56
heat shock proteins, 57
*para* sodium channel gene, 363
sodium channel isoforms, 356
*Duneliella*
protein thermal stability, 56
Duodenal ulcer disease
*Helicobacter pylori* and, 574
DUPAN-2, 610
Dynamic light scattering
mucin and, 642–43

E

ECE
See Endothelin-converting enzyme
Echidnas
body temperatures, 72
metabolic rates, 73
ECMO
See Extracorporeal membrane oxygenation

Ectotherm(s)
diurnal behavioral thermoregulation, 70
enzymes
cold acclimation, 50
Ectothermic poikilothermy, 69
Ectothermy
lamellar-zonal bone and, 87
Edmonds, B., 469–88, 495–513
EDNO
See Endothelium-derived nitric oxide
EDRF
See Endothelium-derived relaxing factor
EGF
See Epidermal growth factor
Elastase
leukocyte adherence in postcapillary venules and, 318
mucin secretion and, 597
surfactant subtype conversion and, 141
Elasticity
mucus gels/mucin solutions and, 645–46
Electrolytes
See Fluids and electrolytes
Electron microscopy
mucin and, 640
*Electrophorus*
acetylcholine receptor, 475
ELISA
See Enzyme-linked immunosorbent assay
ELLA
See Enzyme-linked lectin assay
EMA
See Epithelial membrane antigen
Enalapril
progressive renal disease and, 286
Endocytosis
receptor-mediated
alveolar type II cells and, 136
Endoplasmic reticulum (ER)
iodoplatinate reaction products and, 572
mucin synthesis and, 585–87
Endothelial cells
leukocyte adhesion, 102–5, 318–19
nitric oxide synthesis, 741
platelet-derived growth factor and, 299
stretch-activated cation channels, 334
Endothelial dysfunction
nitric oxide and, 780–82
Endothelial signaling, 827–60
Endothelin, 172–75
nitric oxide formation and, 684
platelet-derived growth factor and, 301
Endothelin-1 (ET-1)
vasoactive properties, 122
Endothelin-converting enzyme (ECE), 172
Endothelium, 171–84
atherosclerotic lesions and, 793–95
endothelins, 172–75
leukocyte traffic and, 830–59
structure-function relationship, 181–82
Endothelium-derived nitric oxide (EDNO), 176–79
fetal pulmonary circulation and, 120–22, 125
Endothelium-derived relaxing factor (EDRF), 120, 172, 176–79, 660, 669, 707–9, 771
Endothelium-derived substances
crosstalk network, 182–84
Endotherm(s)
resting metabolic rates
cellular-subcellular energy sources and, 78
Endothermic homeothermy, 69, 72, 76
Endothermy
avian, 69–91
evolutionary physiology, 72–82
fossil record, 82–83
cellular physiology, 77–82
fibro-lamellar bone and, 87
fossil evidence, 82–89
mammalian, 69–91
evolution, 83–85
evolutionary physiology, 72–82
fossil record, 82–83
at organ and tissue level, 76–77
reptilian
evolution, 83–85
Endotoxic shock
C-natriuretic peptide and, 181
Endotoxin
C-natriuretic peptide secretion and, 180
Energy metabolism
nitric oxide and, 752–53
Enteric nervous system
nitrergic transmission, 660
Enzymatic eurythermality mechanisms, 51–54
Enzyme-linked immunosorbent assay (ELISA)
secreted mucins and, 593
Enzyme-linked lectin assay (ELLA)
secreted mucins and, 593
Enzymes
ectotherm
cold acclimation, 50
nitric oxide and, 690–91
orthologous homologues
conservation of $K_m$ values, 48
Eosinophils
adhesion molecules, 104–5
generation of hypobromous acid and, 246
leukocyte chemoattractants and, 835
Epidermal growth factor (EGF)
compensatory renal growth and, 267
Epinephrine
endothelin-1 gene expression and, 173
hepatic glucose production and, 201–6
Episialin, 609–10
proteolytic cleavage in endoplasmic reticulum, 586
Epitectin, 610
Epithelial cells
matrix protein synthesis
transforming growth factor-β and, 281
nitric oxide synthases, 162
Epithelial membrane antigen (EMA), 610
Epithelial mucin(s)
molecular architecture, 635–36
Epithelial mucin genes, 607–27
Epithelium
calcium/calmodulin-dependent protein kinase and, 434–35
ER
See Endoplasmic reticulum
Erlich ascites tumor cells
stretch-activated cation channels, 334
Erythrocytes
homeoviscous adaptation and, 26
intracellular $Ca^{2+}$ concentration, 9–10
magnesium extrusion, 12
nitric oxide and, 665
transit times in pulmonary circulation, 98–100
transmembrane transport, 4
*Escherichia coli*
endotoxin
neutrophil emigration and, 107–9
membrane lipids, 19
Estivation, 73
ET-1
See Endothelin-1
Ethacrynic acid
nitrergic transmitter and, 670

Ethanol
mucosal phospholipid metabolism/hydrophobicity and, 574
7-Ethoxyresorufin
nitric oxide synthase and, 665
N-Ethylmaleimide
nitrergic transmitter and, 670–71
Eubacteria
hyperthermophilic, 44
Eurytherm(s)
thermal sensitivity of proteins, 51–52
Eurythermality
enzymatic mechanisms, 51–54
Excitatory synaptic currents, 495–512
Exercise
glucose fluxes and, 191–212
hepatic glucose production and, 199–206
Exocytosis
compound, 588–92
Extracellular fluid
chemoattractant formation
hydrogen peroxide and, 314
Extracorporeal membrane oxygenation (ECMO)
persistent neonatal pulmonary hypertension and, 129

F

Fatty acids
mechanotransduction and, 346
Fatty streak, 792
Female reproductive axis, 219–37
Ferricyanide
nitric oxide synthase electron transfer and, 719–20
Fetal circulation
normal, 119
Fetal lung
metabolic function, 128–29
Fibrinolysis
serine proteases and, 142
Fibroblast(s)
endothelin-1 and, 174–75
nitric oxide synthases, 162
nitric oxide synthesis, 741
Fibroblast growth factor (FGF)
endothelium and, 795
smooth muscle cells and, 796
Fibrofatty lesion, 792
Fibrogenesis
transforming growth factor-β and, 280–81
Fibronectin
diabetic nephropathy and, 282
transforming growth factor-β and, 281
Fibrosis
myocardial
collagen and, 814–15
Fibrous plaque, 792–93
FIMs
See Frog integumentary mucins
Fineman, J. R., 115–31
Fischer, T. A., 805–21
Fish
deep body temperatures, 70
Flavins
nitric oxide synthase, 717
Fluids and electrolytes
co-secretion with mucin, 599–600
fMLP
See Formyl methionine leucine proline peptide
Follicle maturation
inhibin and, 232
Follicle-stimulating hormone (FSH), 219
Follicular maturation
activin and, 233–34
Follistatin
embryonic expression, 236–37
identification, 221
mRNA and protein localization in ovary, 229–30
outside reproductive axis, 221–22
radioimmunoassay, 227
Formyl methionine leucine proline peptide (fMLP)
circulating polymorphonuclear leukocytes and, 105–6
Forskolin
cardiac chloride channel and, 390
mucin secretion and, 598–99
nicotinic acetylcholine receptor and, 485
Forstner, G., 585–601
Framingham Heart Study, 805
Franchimont assay, 225
Frank-Starling mechanism, 806
Frog integumentary mucins (FIMs), 624–26
FSH
See Follicle-stimulating hormone
Fucose
salivary mucin biosynthesis and, 553
*Fundulus heteroclitus*
allozyme variants, 52–53
LDH-B allozyme system
cold acclimation, 50

G

Gadsby, D. C., 387–410
Galactose
salivary mucin biosynthesis and, 553
Gamma-aminobutyric acid receptor
open-channel states, 459
Garthwaite, J., 683–700
Gastointestinal mucosa
hydrophobicity
gastroprotective agents and, 576–78
Gaston, B., 151–65
Gastric juice, 565
Gastric mucin, 622
Gastric mucosal barrier
exogenous phospholipids and, 578–79
Gastric mucus
acid environment of stomach and, 648
Gastritis
*Helicobacter pylori* and, 574
Gastrointestinal mucosa
exogenous phospholipids and, 578–79
hydrophobicity
ulcerogenic agents and, 574–76
localization of lipids, 571–74
phospholipid remodeling enzymes, 569–70
surface
hydrophobic characteristics, 568–67
Gastrointestinal mucus
hydrophobicity, 565–79
surface-active lipids and, 569–71
Gastroprotection, 577
Gastroprotective agents
gastrointestinal mucosal hydrophobicity/lipid metabolism and, 576–78
*Gekko gecko*
lens crystallins
temperature of 50% loss of structure, 47
Gelatinase
production by mesangial cells
lipid peroxidase and, 250
Gelation
mucin and, 647–40
Gel chromatography
mucin and, 640
Gendler, S. J., 607–27
Gene expression
calcium/calmodulin-dependent protein kinase and, 435–37
mucin, 626
steroid hormones and, 6
Genetic engineering
protein thermal stability and, 55
Geranylgeranylacetone

gastroprotective mechanisms, 578
GFR
See Glomerular filtration rate
Gibb, A. J., 469–88, 495–513
*Gillichthys mirabilis*
cytosolic malate dehydrogenase isoforms
thermal stability, 54
heat shock response, 59
*Gillichthys seta*
$A_4$-lactate dehydrogenase kinetic properties, 48
thermal sensitivity of proteins, 51–52
Glial cells
nitric oxide formation, 685
Glibenclamide
cardiac chloride channel and, 405
Global warming, 44
Glomerular cells
platelet-derived growth factor and, 299
Glomerular disease
animal models, 254–55
manifestations, 249
reactive oxygen metabolites and, 247–55
Glomerular filtration rate (GFR)
compensatory renal growth and, 266
glomerular disease and, 249–51
Glomerular injury
antioxidant defenses and, 256–58
Glomerulonephritis
angiotensin-converting enzyme inhibitors and, 286
anti-glomerular basement membrane-induced, 247
experimental
transforming growth factor-β and, 281–82
pauci-immune crescentic, 247
pauci-immune necrotizing anti-myeloperoxidase antibodies and, 253
platelet-derived growth factor and, 303
Glomerulosclerosis
hyperfiltration and, 287–90
mesangial cell proliferation and, 288–89
transforming growth factor-β and, 279
Glucagon
hepatic glucose production and, 201–6
Glucocorticoids
hepatic glucose production and, 205
superoxide dismutase activity and, 257
Gluconeogenesis
hepatic
mechanisms, 200–1
Glucose
hypokalemic periodic paralysis and, 366
Glucose fluxes
exercise and, 191–212
Glucose utilization
muscle
contraction-stimulated, 192–94
insulin-independent, 194–97
Glutamate
calcium/calmodulin-dependent protein kinase and, 423, 429
nitric oxide and, 693
Glutamate receptor, 495–512
nitric oxide and, 683–84
Glutamatergic synapse
synaptic cleft
time course of transmitter, 512–13
Glutathione
nitrergic transmitter and, 671
Glutathione peroxidase
reduction of hydrogen peroxide to water and, 256–57
Glyceraldehyde-3-phosphate dehydrogenase
nitric oxide and, 690–91, 752
Glycerol
hepatic gluconeogensis and, 201
protein thermal stability and, 56
Glycogenolysis
hepatic
mechanisms, 200–1
Glycolysis
nitric oxide and, 690, 752
Glycosylation
mucin synthesis and, 586–87
salivary mucin biosynthesis and, 553–55
Goblet cells
mucin secretion and, 588–91
parasite rejection and, 596
ulcerative colitis and, 587–88
Goldman-Hodgkin-Katz constant field equation, 402
Golgi
mucin synthesis and, 585–87
Gonadotropin-releasing hormone
nitric oxide synthase and, 694
G proteins
cardiac chloride channel and, 390–92
Granger, D. N., 311–24
Granulocytes
ischemia/reperfusion injury and, 315
neutrophilic
functions, 829
Granuloma formation
intercellular adhesion molecule-1 and, 842
Griffith, O. W., 707–30
Groome ELISA, 225
Gross, N. J., 135–48
Gross, S. S., 737–60
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI), 819
Guanylate cyclase
inhibition, 667–68
mucin secretion and, 596
Guanylyl cyclase
nitric oxide and, 686–90, 749–50
nitrogen oxides and, 162–63
Gut homing lymphocytes, 855–56

H

H23 antigen, 610
Haber-Weiss reaction, 254
metal-catalyzed, 246
Haptotaxis, 835
Hazel, J. R., 19–37
hCG
See Human chorionic gonadotropin
HCVD
See Hypoxic coronary vasodilation
Heart
calcium/calmodulin-dependent protein kinase, 427, 431
cystic fibrosis transmembrane regulator, 387–410
ischemia/reperfusion injury
leukocytes and, 315
renin-angiotensin system, 809–11
sodium channel genes
chromosomal localization, 362–63
sodium channel subunit, 358
Heart disease
cyanotic
glomerular sclerosis and, 272
Heart Outcomes Prevention Evaluation (HOPE), 820
Heat shock element (HSE), 60
Heat shock factor (HSF), 60
Heat shock proteins (hsps), 44
induced thermal tolerance and, 57–58
interspecific variations, 60

protein thermal stability and, 61–62
Heat shock response, 44, 57–61
evolutionary and acclimatory changes, 59–60
*Helicobacter pylori*
chronic active gastritis and, 574
gastrointestinal mucosal hydrophobicity and, 575–76
Hematocrit
pulmonary vascular resistance and, 118
Heme
nitric oxide synthase and, 722–23
reactions with nitric oxide, 746–47
Hemoglobin
nitric oxide and, 749
Hemoproteins
nitric oxide and, 749
Hemostasis
serine proteases and, 142
Heparin-binding epidermal growth factor-like growth factor
smooth muscle cells and, 796
Hepatic glucose production
role and regulation during exercise, 199–206
Hepatocytes
homeoviscous adaptation and, 26
HEV
See High endothelial venule
Hexokinase II
glucose phosphorylation and, 194
Hexose monophosphate shunt (HMPS), 257
Heymann, M. A., 115–31
Hibernation, 73
High endothelial venule (HEV), 101, 829
binding assay, 849–51
inflammation and, 857
lymphocyte trafficking and, 849, 851–54
Hippocampus
serotonin receptor and, 449
Histamine
cAMP content in glomeruli and, 252
cardiac chloride channel and, 390
endothelial function and, 831
mucin secretion and, 597
postnatal pulmonary vascular tone and, 128
P-selectin upregulation and, 104
Histone
leukocyte adhesion and, 318
HMPS
See Hexose monophosphate shunt
Hogg, J. C., 97–111
Homeophasic adaptation (HPA), 32–33
Homeostasis
salt
angiotensin II and, 284
Homeothermy
endothermic, 69, 72, 76
inertial, 70
Homeoviscous adaptation (HVA), 19–37
membrane remodeling and, 23–31
Hoover, R., 171–84
HOPP
See Hypokalemic periodic paralysis
Hostetter, T. H., 263–75
HPA
See Homeophasic adaptation
HSE
See Heat shock element
HSF
See Heat shock factor
hsps
See Heat shock proteins
Human chorionic gonadotropin (hCG)
inhibin production and, 233
Humans
heat production at rest, 76
HVA
See Homeoviscous adaptation
Hwang, T.-C., 387–410
Hydralazine
aortic fibronectin mRNA expression and, 815
Hydrogen ions
gastric mucus and, 648
Hydrogen peroxide
cellular detoxification, 256–57
chemoattractant formation in extracellular fluid and, 314
generation by mesangial cells, 248
glomerular disease and, 255
proteinuria and, 251
sequential reduction of oxygen and, 245–46
Hydrophobic interactions
protein stabilization and, 61
Hydrophobicity
gastrointestinal mucus, 565–79
protein thermal stability and, 55
Hydroxocobalamin
nitric oxide inactivation and, 666
Hydroxyapatite
salivary mucins and, 556–57
5-Hydroxyindole
serotonin receptor channel and, 462
Hydroxytoluene
mammalian cells at low temperatures and, 22
5-Hydroxytryptamine
See Serotonin
Hyperkalemic periodic paralysis (HYPP), 366
identification of channels containing disease mutations, 373–76
linkage analysis, 369–70
physiologic studies, 368–69
sodium channel mutations, 370–72
Hyperplasia
compensatory hypertrophy and, 263
Hypersensitivity
delayed-type
intercellular adhesion molecule-1 and, 842
Hypertension
compensatory nitric oxide synthesis and, 782–83
endothelin and, 175
endothelium-dependent vasorelaxation and, 178
nitric oxide synthesis inhibition and, 776–77
pulmonary
persistent of newborn, 115, 129–31
Hyperthermophiles, 44
protein stabilization
inorganic ions and, 56
Hypertrophy
cardiac
renin-angiotensin system and, 285
compensatory, 263
myocyte
angiotensin II and, 813–14
Hypobromous acid
generation by eosinophils, 246
Hypochlorous acid
formation in biologic systems, 246
neutrophil-derived, 312
Hypoglycemia
marathon exercise and, 191
Hypokalemic periodic paralysis (HOPP), 366
physiologic studies, 368
Hypotension
nitric oxide and, 179
Hypothalamo-pituitary axis
nitric oxide and, 694
Hypothalamus
C-natriuretic peptide, 180

Hypoxanthine-xanthine oxidase
neutrophil infiltration and, 314
Hypoxic coronary vasodilation (HCVD)
nitric oxide and, 774–75
HYPP
See Hyperkalemic periodic paralysis

I

IBMX
See Isobutylmethylxanthine
ICAMs
See Intercellular adhesion molecules
IgA nephropathy
platelet-derived growth factor and, 303
IGF-1
See Insulin-like growth factor-1
IgG
oxidative burst and, 247
Immune complexes
oxidative burst and, 247
superoxide/hydrogen peroxide generation and, 248
Immune-mediated tissue injury
reduced oxygen metabolites and, 245
Immunoglobulin superfamily
leukocyte-endothelial cell adhesion and, 103–4
leukocyte trafficking and, 840–41
Inagami, T., 171–84
Inclusion bodies
large infranuclear, 572
Indeterminacy principle, 5
Indomethacin
mucin secretion and, 596
pulmonary vascular resistance and, 124
Inertial homeothermy, 70
Inflammation
alteration in lymphocyte trafficking, 856–59
neutrophil emigration and multi-step model, 842–45
reactive oxygen metabolites and, 246
Inflammatory bowel disease
MUC2 and, 617
Inflammatory cytokines
adhesion molecules and, 830–31
Inflammatory mediators
mucin secretion and, 596–97
Inflammatory response
adhesion molecules and, 108
transforming growth factor and, 103
Infrared spectroscopy
mucin and, 640
Inhibin
binding proteins, 234–35
binding sites in ovary, 230–31
bioassays, 222
second generation, 224–25
cancer and, 232–33
embryonic expression, 236–37
follicular maturation and, 232
identification, 219–20
menstrual cycle and, 223–24
mRNA and protein localization in ovary, 229–30
outside reproductive axis, 221–22
pituitary and ovarian response, 231–32
radioimmunoassay, 222–23
subunit characterization, 220
Inorganic ions
protein thermal stability and, 56–57
Insulin
endothelin-1 and, 173
hypokalemic periodic paralysis and, 366
working muscle and, 197–99
Insulin-like growth factor 1 (IGF-1)
compensatory renal growth and, 267
endothelium and, 795
Integrins
activation, 837–40
adhesiveness, 837
leukocyte-endothelial cell adhesion and, 103–4
leukocyte-endothelial interactions and, 838
neutrophil emigration and, 842–44
transforming growth factor-β and, 281
Intercellular adhesion molecules (ICAMs)
atherogenesis and, 794
Interferon
leukocyte migration and, 102
Interferon-γ
nitric oxide synthase and, 739–40
Interleukin(s)
C-natriuretic peptide secretion and, 180
endothelial adhesiveness and, 830
endothelium and, 795
leukocyte migration and, 102–3
nitric oxide synthase and, 739–40
Interleukin 1
mucin secretion and, 597
Interleukin 2 gene expression
calcineurin and, 437
International Study of Infarct Survival (ISIS), 818–19
Interneurons
serotonin receptor and, 449
Intestinal anaphylaxis
mucin secretion and, 597
Intestinal mucins, 615–19
schematic, 636
Intestine
calcium/calmodulin-dependent protein kinase, 427
Iodoplatinate technique, 571–72
Ion channels
neuromuscular disease and, 363
nitric oxide and, 692
IPC
See Ischemic preconditioning
Iron
nonheme
reactions with nitric oxide, 746–47
release
nitric oxide and, 754–56
Ischemia/reperfusion injury, 311–24
ischemic preconditioning and, 322–24
leukocytes and, 315–21
nitric oxide and, 759–60
reactive oxygen metabolites and, 312–15
Ischemic preconditioning (IPC)
ischemia/reperfusion injury and, 322–24
Ischemic tissue injury
reduced oxygen metabolites and, 245
Isobutylmethylxanthine (IBMX)
cardiac chloride channel and, 393
Isoproterenol
cardiac chloride channel and, 390–91
mucin secretion and, 596
Isosorbide dinitrate
mucin secretion and, 596

J

Jackson, M. B., 447–65
JGA
See Juxtaglomerular apparatus
Juxtaglomerular apparatus (JGA)
nitric oxide and, 778–79

K

Kainate receptor, 508
central nervous system, 508–9
nitric oxide formation and, 684
Ketteler, M., 279–91

Kidney
angiotensin II receptors, 284
calcium/calmodulin-dependent protein kinase, 427
compensatory growth, 264–67
ischemia/reperfusion injury
leukocytes and, 315
microcirculation
nitric oxide and, 778–79
nitric oxide synthase inhibition and, 779–80
platelet-derived growth factor and, 299–302
tissue development
platelet-derived growth factor and, 306
Kidney cells
stretch-activated cation channels, 334
Kidney disease
platelet-derived growth factor and, 302–6
progressive
compensatory growth and, 271–75
mechanisms, 267–71
transforming growth factor-β and, 281–83
Kidney failure
progressive
angiotensin II and, 285–87
Korthuis, R. J., 311–24
Krebs cycle, 752

L

Lactate
hepatic gluconeogensis and, 201
Lactate dehydrogenase (LDH)
orthologous homologues
conservation of $K_m$ values, 48
Lactoferrin
leukocyte adherence in postcapillary venules and, 318
Lamellar bodies, 135–36
convertase activity, 143
LaMont, J. T., 635–53
La Place relation, 274
Large infranuclear inclusion body (LIIB), 572
LDH
See Lactate dehydrogenase
Left ventricular overload
cardiac renin-angiotensin system and, 811
Lens
stretch-activated cation channels, 336–37
Lens crystallins
temperature of 50% loss of structure, 47
Leukocyte(s)
bactericidal oxidants, 246
functions, 829–30
ischemia/reperfusion injury and, 315–21
proteinuria and, 249
Leukocyte adhesion
endothelial cells and, 102–5
Leukocyte margination
pulmonary and systemic microvessels and, 102
Leukocyte migration, 102
Leukocyte traffic, 97–111, 827–60
bronchial circulation and, 100–111
endothelial, 830–59
pulmonary circulation and, 97–100
Leukotrienes
asthma and, 155–56
biological actions, 154–56
fetal pulmonary vascular resistance and, 120
interactions with tachykinins, 161
postischemic tissues and, 315
pulmonary airway tone and, 151–56
synthesis, 151–54
Levi, R., 771–84
LH
See Luteinizing hormone
Li, C. G., 659–74
Lichtenberger, L. M., 565–79
Light-chain deposition disease
platelet-derived growth factor and, 303
Light scattering
mucin and, 641–43
LIIB
See Large infranuclear inclusion body
Linoleic acid
plasma membranes and, 79
Lipase
sodium pump and, 10
Lipid(s)
behavior and properties in membranes
temperature and, 19
calcium pump and, 10–11
Golgi secretory activity and, 34
localization in gastrointestinal mucosa, 571–74
Lipid metabolism
gastroprotective agents and, 576–78
ulcerogenic agents and, 574–76
Lipid peroxidase
production of gelatinase by mesangial cells and, 250
Lipopolysaccharide (LPS)
leukocyte migration and, 830
nitric oxide synthase and, 739–40
Lipoxygenase
nitric oxide and, 749
5-Lipoxygenase activating protein
leukotriene synthesis and, 154
Liver
angiotensin II receptors, 284
calcium/calmodulin-dependent protein kinase, 427
glucose production
role and regulation during exercise, 199–206
glycogenolysis/gluconeogenesis
mechanisms, 200–1
Lizards
diurnal body temperatures, 70
thermoregulation, 73
Long-term depression
nitric oxide and, 698–99
Long-term potentiation (LTP)
calcium/calmodulin-dependent protein kinase and, 429–30
nitric oxide and, 695–97
Losartan
aortic fibronectin mRNA expression and, 814
renin-angiotensin system and, 269
LPS
See Lipopolysaccharide
LTP
See Long-term potentiation
Lung
calcium/calmodulin-dependent protein kinase, 427
ischemia/reperfusion injury
leukocytes and, 315
leukocyte traffic, 97–111
surfactant convertase and, 143–44
Lupus nephritis
platelet-derived growth factor and, 303
Luteinizing hormone (LH)
inhibin production and, 223
nitric oxide synthase and, 694
LY-83583
guanylate cyclase inhibition and, 667–68
Lymphocyte(s)
gut homing, 855–56
memory
recirculation, 854–56
mucus secretagogues and, 597
recirculation, 847–49

skin homing, 855
Lymphocyte trafficking
alteration in inflammation, 856–59
mucin-like glycoproteins and, 607

M

Macrophages
alveolar, 108
C-natriuretic peptide, 179
monocyte-derived
atherosclerotic lesions and, 797–98
mucus secretagogues and, 597
nitric oxide synthases, 162
oxidative metabolism, 247
Magnesium
extrusion from erythrocytes, 12
Malate dehydrogenase (MDH)
thermal stability, 46, 54
MAM-6, 610
Mammal(s)
activity metabolism, 74–75
evolution of endothermy, 69–91
oxygen delivery systems, 75–76
temperature set point and resting metabolic rate, 72–73
thermal conductance, 72
Mammalian endothermy, 69–91
evolution, 83–85
evolutionary physiology, 72–82
fossil evidence, 82–83
Marsupial mammals
body temperatures, 72
Mast cells
C-fiber interactions, 159
nitric oxide synthases, 162
tachykinin activation, 160
Mather, J. P., 219–37
Matrix proteins
transforming growth factor-β and, 281
M&B 22948
pulmonary vasodilation and, 128
McGehee, D. A., 521–41
MCP
See Monocyte chemoattractant protein
M-CSF
See Monocyte-colony stimulating factor
MDH
See Malate dehydrogenase
Mechanosensitive channels, 333–49
cellular currents and, 347–49
functional classification, 334–40
properties, 340–42
theories of activation, 343–47
Meclofenamic acid
pulmonary vascular resistance and, 124
Medginix assay, 232–33
Membrane(s)
constraints to growth and function, 21–22
structure and function
thermal perturbation, 20–21
Membrane-associated mucins, 609–14
Membrane attack complex
superoxide/hydrogen peroxide generation and, 248
Membrane remodeling
adaptive explanations, 23–36
thermal adaptation and, 22–23
Membranoproliferative glomerulonephritis
platelet-derived growth factor and, 303
Memory lymphocytes
recirculation, 854–56
Menstrual cycle
activin and, 227–29
inhibin and, 223–24
Mesangial cells
gelatinase production
lipid peroxidase and, 250
generation of superoxide/hydrogen peroxide, 248
matrix protein synthesis
transforming growth factor-β and, 281
platelet-derived growth factor and, 299
proliferation
glomerulosclerosis and, 288–89
Metabolism
activity
in reptiles, birds, mammals, 74–75
*Methanothermus fervidus*
protein thermal stability, 56
Methoxamine
mucin secretion and, 594–95
Methylene blue
guanylate cyclase inhibition and, 667
Microcystin
cardiac chloride channel and, 393–94, 435
Microglial cells
nitric oxide formation, 685
*Micropterus salmoides*
allozyme variants, 52–53
Mineralocorticoids
sodium-potassium pump and, 6–7
Minoxidil
cardiac chloride channel and, 405
Mitochondria
homeoviscous adaptation and, 25
Mitochondrial membranes
cytochrome c inactivation temperature and, 27
Mitochondrial respiration
nitric oxide and, 752
Monash RIA, 222, 224, 225
Monensin
mucin synthesis and, 587
Monocyte(s)
adhesion molecules, 104–5
emigration
signaling, 845–46
functions, 829
leukocyte chemoattractants and, 835
oxidative metabolism, 247
Monocyte chemoattractant protein (MCP), 253
Monocyte-colony stimulating factor (M-CSF)
smooth muscle cells and, 796
Monotremes
body temperatures, 72
metabolic rates, 73
Monovalent cations
serotonin receptor channel and, 452–53
Mouse neuroblastoma cell lines
serotonin receptors, 449
MPO
See Myeloperoxidase
MUC1, 609–14
functions, 613–14
MUC1 gene
protein structure, 610–11
regulation, 611–12
MUC2, 615–18
MUC3, 619
MUC4, 619
MUC5A, 619–21
MUC5C, 621
MUC6, 622
MUC7, 622–23
MUC176, 619
Mucin(s), 585–601
agonists and receptors, 594–97
biophysical properties
study techniques, 640–41
biophysics, 635–53
domains
function, 636–37
dynamic light scattering and, 642–43
epithelial
molecular architecture, 635–36
frog integumentary, 624–26

gastric, 622
intestinal, 615–19
schematic, 636
intracellular processing, 585–88
intracellular signal transduction and, 597–99
membrane-associated, 609–14
nuclear magnetic resonance and, 644–45
polymerization and gelation models, 647–40
salivary, 547–60
alimentation and, 555
biosynthesis, 552–55
function, 555–58
oligosaccharides, 551–52
oral flora and, 557–58
as oral therapeutics, 558–60
structure, 548–52
suprastructure, 551
tissue coating and, 555–57
salivary gland, 622–24
secreted, 614–26
secretion, 588–600
fluid and electrolyte co-secretion, 599–600
regulated, 591–94
unregulated, 589–91
sedimentation velocity/equilibrium and, 643–44
static light scattering and, 641–42
tracheobronchial, 619–21
Mucin gels
diffusion of macromolecules, 647
hydrodynamic properties, 647–53
Mucin genes
cloned
sequences of tandem repeats, 608
epithelial, 607–27
expression, 626
Mucin-like molecules
leukocyte trafficking and, 831–32
Mucin solutions
viscoelastic properties, 645–46
Mucosa
gastrointestinal
hydrophobic characteristics, 568–67
localization of lipids, 571–74
oxyntic
gradient of reactivity, 572
Mucous cells
staining, 571–72
Mucus, 547, 635
gastric
acid environment of stomach and, 648
gastrointestinal
hydrophobicity, 565–79
Mucus acinar cells, 547
Mucus gels
diffusion of macromolecules, 647
swelling behavior, 646–47
viscoelastic properties, 645–46
Muscarinic cholinoceptors
nitrergic nerve terminals and, 665
Muscle
action potentials
membrane voltage-dependent sodium channels and, 355
birefringence, 3
nicotinic acetylcholine receptor, 469–88
structure, 475–78
working
insulin action, 197–99
regulation of glucose utilization, 192–99
Muscle contraction
endocrine, neural, hepatic responses and, 206–11
Muscle disease
sodium channels and, 363–68
Muscle spindles
mechanosensitive channels, 333
Mustard oil
mucin secretion and, 597
Myasthenia gravis
nicotinic acetylcholine receptor and, 363
Myeloperoxidase (MPO)
formation of hypochlorous acid and, 313
neutrophil-derived
reactive oxygen metabolites and, 246
Myeloperoxidase-hydrogen peroxide-halide system
neutrophil-mediated immune complex glomerulonephritis and, 251
Myenteric plexus
serotonin receptor activation and, 448–49
Myocardial fibrosis
collagen and, 814–15
Myocardial infarction, 805–21
angiotensin-converting enzyme inhibition and, 811–15
lesions of atherosclerosis and, 791
ventricular remodeling and, 807–8
Myocyte hypertrophy
angiotensin II and, 813–14
Myoglobin
nitric oxide and, 749
Myosin
endothelin-1 and, 182
Myosin light chain
isoforms
acclimation temperature and, 53
phosphorylation
xanthine-xanthine oxidase system and, 252
Myosin light chain kinase, 418
calcium/calmodulin-dependent protein kinase and, 433–34
Myotonia
hyperkalemic periodic paralysis and, 366
paramyotonia congenita and, 367
sodium channel, 367–68
physiologic studies, 369
Myotonic dystrophy, 367
*Mytilus edulis*
cryoprotectants, 56

N

NADH-ubiquinone oxidoreductase
nitric oxide and, 690, 752
NADPH oxidase
postischemic tissues and, 313
NADPH oxidation
nitric oxide synthase and, 718–19
Nagel, G., 387–410
Naruse, M., 171–84
Natriuretic peptides, 179–81
endothelin-1 gene expression and, 173
Natural selection
protein thermal stability and, 47–48
NCRC11 antigen, 610
Necrotizing vasculitis
pauci-immune, 247
Nephrectomy
compensatory renal growth and, 264–67
Nephritis
lupus
platelet-derived growth factor and, 303
passive Heymann, 255
Nephropathy
AIDS
glomerular sclerosis and, 272
diabetic
angiotensin-converting enzyme inhibitors and, 286, 289–90

end-stage renal failure and, 282
platelet-derived growth factor and, 305
IgA
platelet-derived growth factor and, 303
reflux
glomerular sclerosis and, 272
Nephrotic syndrome, 248
adriamycin-induced, 255, 274
puromycin aminonucleoside-induced, 249, 254–55
Nervous system
calcium/calmodulin-dependent protein kinase and, 427–31
Neuroblastoma cells
stretch-activated cation channels, 334
Neurokinin A
pulmonary C-fibers and, 157
Neuromedin N
mucin secretion and, 595
Neuromodulators
nitric oxide formation and, 684
Neuromuscular disease
pathogenesis
ion channels and, 363
Neuron(s)
calcium/calmodulin-dependent protein kinase and, 428–29
nitric oxide formation, 684–85
nitric oxide synthases, 162
Neuronal firing
nitric oxide and, 691–92
Neuropeptides
neural synthesis and release, 156–57
pulmonary airway tone and, 156–61
Neurotensin
mucin secretion and, 595
Neurotransmitter(s)
calcium/calmodulin-dependent protein kinase and, 429–31
nitric oxide and, 659–74, 684, 693
Neurotransmitter receptors
nitric oxide and, 693–94
Neutron scattering
mucin and, 640
Neutrophil(s)
adhesion molecule receptor, 103–4
calcium/calmodulin-dependent protein kinase, 434
cold shock and, 58
emigration
signaling, 845–46
emigration in inflammation
multi-step model, 842–45
leukocyte chemoattractants and, 835
nitric oxide and, 756
nitric oxide synthases and, 162
oxidative metabolism, 247
adenosine and, 322
oxygen metabolites, 246
*Streptococcus pneumoniae* and, 106–9
transendothelial cell migration, 104
Neutrophilic granulocytes
functions, 829
Newborn
persistent pulmonary hypertension, 115, 129–31
Nicotinic acetylcholine receptor
calcium permeability, 454
evidence for diversity, 522
muscle, 469–88
activation, 472–73
agonist mechanisms, 478–86
channel modes, 481–82
desensitization, 482–85
experimental methods, 474–75
phosphorylation, 485
single-channel currents, 470–72
structure, 475–78
synaptic currents, 470–72, 486–87
myasthenia gravis and, 363
neuronal, 521–41
biophysical characteristics, 527–30
calcium permeability, 535–36
functional domains, 530–31
presynaptic, 536–37
subtypes, 531–34
subunit combinations in *Xenopus* oocytes, 524–32
subunit composition, 534–35
subunit gene family, 522–24
synaptic transmission and, 537–38
targeting, 538–39
open-channel states, 459
Nile red
mucous cell staining and, 571
*Nippostrongylus brasiliensis*, 596
Nitreregic transmitter
composition, 668–71
Nitrergic nerve terminals
histological localization, 660
ultrastructure, 672–73
Nitrergic transmission, 659–74
blockade, 663–68
evidence, 659–61
mechanism, 671–74
physiological role, 661
Nitric oxide (NO)
antioxidant defense and, 756–57
biological chemistry, 742–49
blockade of action on effector tissues, 667–68
blood pressure and, 771–84
cellular targets, 749–57
cerebral blood flow and, 699–700
circulatory shock and, 758–59
compensatory synthesis in hypertension, 782–83
cyclic GMP and, 686–90
DNA synthesis and, 753–54
endothelial
synthesis, 772–74
endothelial dysfunction and, 780–82
endothelin-1 gene expression and, 173
endothelium and, 176–79
endothelium-derived, 176–79
fetal pulmonary circulation and, 120–22, 125
energy metabolism and, 752–53
hypoxic coronary vasodilation and, 774–75
hyptotensive effects in vivo, 775
inactivation, 665–66
inhibition of release, 665
inhibition of synthesis, 663–65
ion channel modulation and, 692
iron release and, 754–56
ischemia/reperfusion injury and, 321, 759–60
long-term depression and, 698–99
long-term potentiation and, 695–97
metabolism
stable products, 748–49
mucin secretion and, 596
neuronal firing and, 691–92
neuronal/neuroendocrine function and, 691–94
as neurotransmitter in peripheral nerves, 659–74
neurotransmitter receptors and, 693–94
neurotransmitter release/uptake and, 693
nitrergic nerve stimulation and, 661
overproduction
molecular mechanisms, 738–39
pathophysiological mechanisms, 737–60

persistent neonatal pulmonary hypertension and, 129–30
presynaptic neurotransmitter release and, 429–30
properties in solution, 743–44
reactions with amines, 748
reactions with heme/nonheme iron, 746–47
reactions with superoxide anion, 746
reactions with thiols, 747–48
regulation of formation, 684–85
renal microcirculation and, 778–79
renin release and, 778–79
signaling in central nervous system, 683–700
signal transduction and, 686–91, 749–52
soluble guanylyl cyclase and, 686–90
spread by diffusion, 685–86
superoxide-mediated leukocyte adherence and, 320–21
synaptic plasticity and, 694–99
synthesis inhibition
hypertensive effects, 776–77
synthesis in vivo
substrate limitation, 783–84
vascular pharmacology, 772
Nitric oxide synthase (NOS), 161–62, 707–30
amino acid inhibitors, 728
arginine analogues and, 727–28
autoinactivation, 723–24
calmodulin binding, 716
catalytic mechanism, 709–10
cell and tissue distribution, 712–13
cofactors, 717–22
coupled reactions, 717–19
cytochrome P450 and, 722–23
domain organization, 714–16
heme cofactor, 722–23
inhibition, 664–65
hypertensive effects, 776–77
pressor effects, 777–78, 779–80
inhibitors, 726–29, 772–74
isoforms, 710–14, 738–39
nitrergic transmission and, 673–74
non-amino acid inhibitors, 728–29
plasticity, 684–85
prosthetic groups, 738
purification, 713–14
quaternary structure, 716–17
regulation of activity, 739–42
tetrahydrobiopterin and, 725–26
uncoupled reactions, 719–21
Nitrogen oxides
biosynthesis and chemical characteristics, 161–62
mechanisms of action, 162–64
pulmonary airway tone and, 161–65
Nitromimetics, 661–63
Nitroprusside
mucin secretion and, 596
Nitroso-alcohols
nitrergic nerve stimulation and, 661–62
Nitrosocobalamin
nitric oxide inactivation and, 666
Nitrosothiols, 694
nitrergic nerve stimulation and, 662–63
Nitrovasodilator drugs, 752
hypotensive effects, 775
N-linked glycosylation
salivary mucin biosynthesis and, 553
NMDA, 495
NMDA channel
closed times, 500
gating, 504
open times, 500–1
probability of being open, 503–4
NMDA receptor, 495–507
activation
identification, 502–3
mechanism, 504–5
desensitization, 501–2
nitric oxide and, 683, 693, 751
phosphorylation, 506–7
single-channel currents, 499–500
structure, 498–99
synaptic currents
rising phase, 506
time course, 505–6
See also Non-NMDA receptor
N-methyl-D-aspartate
See NMDA
NMR
See Nuclear magnetic resonance
NO
See Nitric oxide
Noble, N. A., 279–91
Nodose ganglion
serotonin receptor activation and, 448–49
single-channel conductance, 455
Non-NMDA receptor, 507–13
activation and desensitization, 509–10
cloned
functional properties, 507–8
desensitization
time course, 497
identity in central nervous system, 508–9
structure, 507
synaptic currents
time course, 510–11
Nonpenetrating glycoprotein (NPGP), 610
Nonshivering thermogenesis (NST), 70
Nonsteroidal antiinflammatory drugs (NSAIDs)
mucosal hydrophobicity and, 574
zwitterionic phospholipids and, 579
Norepinephrine
hepatic glucose production and, 201–6
nitric oxide and, 684, 693
NOS
See Nitric oxide synthase
NPGP
See Nonpenetrating glycoprotein
NSAIDs
See Nonsteroidal antiinflammatory drugs
NST
See Nonshivering thermogenesis
Nuclear magnetic resonance (NMR)
mucin and, 640, 644–45
Nucleoside triphosphates
cardiac chloride channel gating and, 396–401
Nucleus tractus solitarius
serotonin receptor and, 449

O

Obesity
glomerular sclerosis and, 272
O-glycans, 549–51
Okadaic acid
cardiac chloride channel and, 393–94, 435
Olfactory cells
cyclic AMP-operated channels, 687–88
Oligomeganephronia, 272
Oligosaccharides
salivary mucin, 551–52
O-linked glycosylation
salivary mucin biosynthesis and, 553–55
*Oncorhynchus mykiss*
lens crystallins
temperature of 50% loss of structure, 47

Opioid receptor
nitrergic nerve terminals and, 665
Oral cavity
defense, 547–60
Oral flora
salivary mucins and, 557–58
Organic cations
serotonin receptor channel and, 453
Organic molecules
cellular uptake
sodium pumps and, 79
Organic solutes
protein thermal stability and, 56–57
Orthovanadate
cardiac chloride channel and, 397
*Oryzias latipes*
heat shock induction temperatures, 59
Osmium tetroxide
pulmonary surfactant and, 572
Osteoblasts
stretch-activated cation channels, 334, 336–37
Ouabain
sodium-potassium pump and, 7
Ovarian cancer
inhibin and, 232–33
Ovarian-pituitary axis, 221
Ovary
inhibin, activin, follistatin mRNA and protein localization, 229–30
inhibin-/activin-binding sites, 230–31
response to inhibin and activin, 231–32
Oxidants
P-selectin upregulation and, 104
Oxygen
consumption
postnatal pulmonary vascular tone and, 128
delivery systems
in birds and mammals, 75–76
free radicals
mucin secretion and, 597
See also Reactive oxygen metabolites
Oxygenation
extracorporeal membrane
persistent neonatal pulmonary hypertension and, 129
Oxyntic mucosa
gradient of reactivity, 572
Oxytocin
nitric oxide synthase and, 694

P

PAF
See Platelet-activating factor
*Pagothenia borchgrevinki*
lens crystallins
temperature of 50% loss of structure, 47
PAN
See Puromycin aminonucleoside
Pancreas
neural control, 211
Pancreatic phospholipase
surfactant subtype conversion and, 141
Paralysis
periodic, 365–67
hereditary, 365
physiologic studies, 368–69
Paramyotonia congenita (PC), 367
identification of channels containing disease mutations, 376–78
physiologic studies, 368
sodium channel mutations, 372
PAS-0, 610
PC
See Paramyotonia congenita
PCR
See Polymerase chain reaction
PDGF
See Platelet-derived growth factor
Peanut-lectin binding urinary mucin (PUM), 610
PECAMs
See Platelet-endothelial cell-adhesion molecules
PEM
See Polymorphic epithelial mucin
Pentoxyphyllin
platelet-derived growth factor and, 299
Periodic paralysis, 365–67
hereditary, 365
physiological studies, 368–69
Peripheral lymph node high endothelial venule
lymphocyte migration, 851–53
molecules binding, 850
Peripheral nerves
nitric oxide as neurotransmitter, 659–74
Peroxidase
nitric oxide and, 749
Peroxynitrite, 312
formation, 719
Persistent pulmonary hypertension of newborn (PPHN), 115, 129–31
Pertussis toxin
chemoattractant receptors and, 837
lymphocyte emigration and, 857
Peyer's patch high endothelial venule
lymphocyte migration, 853–54
molecules binding, 850–51
Pfeffer, J. M., 805–21
Pfeffer, M. A., 805–21
pH
postnatal pulmonary vascular tone and, 128
pulmonary vascular resistance and, 120
Phagocytosis
respiratory burst and, 247
Phalloidin
venule leakiness and, 182
Phophoslamban
calcium pump and, 431–32
Phorbol esters
endothelin-1 gene expression and, 173
Phorbol myristate acetate
proteinuria/neutrophil depletion and, 251
Phosphatases
cardiac chloride channel and, 393–94
Phosphodiesterases
cardiac chloride channel and, 392
cyclic GMP and, 689
Phospholipase
mucosal phospholipid metabolism/hydrophobicity and, 574
surfactant subtype conversion and, 141
Phospholipase $A_2$
arachidonic acid release from membrane phospholipids and, 153
Phospholipase C activators
mucin secretion and, 594–95
Phospholipids
exogenous
gastric mucosal barrier and, 578–79
plasma membrane leakiness and, 79–80
surfactant, 136–37
Phosphorylation
cardiac chloride channel, 393–96
nicotinic receptor, 485
NMDA receptor, 506–7
Photoreceptor cells
cyclic GMP-operated channels, 687–88

Photosynthesis
low temperature inhibition, 29
Pituitary
C-natriuretic peptide, 180
response to inhibin and activin, 231–32
Placental mammals
body temperatures, 72
reptilian-type energetics, 73
Plant cells
stretch-activated cation channels, 337
Plasma membranes
homeoviscous adaptation and, 25
leakiness, 79–80
thermogenesis and, 80
phase separation, 32–33
Platelet(s)
atherosclerotic lesions and, 799
glomerular injury and, 252
Platelet-activating factor (PAF)
fetal pulmonary vascular resistance and, 122
postischemic tissues and, 315
reactive oxygen metabolites and, 252
superoxide/hydrogen peroxide generation and, 248
Platelet adhesion
nitric oxide and, 782
Platelet aggregation
adenosine and, 322
endothelium-derived relaxing factor and, 176
nitric oxide and, 782
Platelet-derived growth factor (PDGF), 297–307
actions in kidney, 302–3
biology, 297–302
diabetic nephropathy and, 305
endothelium and, 795
fetal pulmonary vascular resistance and, 122
interstitial disease and, 305–6
kidney disease and, 303–5
matrix protein synthesis and, 281
receptors and signaling proteins, 298–99
renal tissue development and, 306
smooth muscle cells and, 796
sources in kidney, 299–302
synthesis and release, 297–98
transforming growth factor-β and, 287
Platelet-endothelial cell-adhesion molecules (PECAMs)
atherogenesis and, 794
Platypus
body temperatures, 72
PMNs
See Polymorphonuclear leukocytes
Pneumonia
leukocyte emigration and, 106
Poikilotherm(s)
eurythermal
temperature acclimation and, 24–26
Poikilothermy
ectothermic, 69
lipid remodeling and, 32
thermal adaptation of membranes and, 19, 20, 22
Poiseuille-Hagen relationship, 117–18
Polymerase chain reaction (PCR)
cyclic nucleotide-gated channels and, 688
heart sodium channel subunit and, 358
Polymerization
actin
chemoattractant receptors and, 837
mucin, 647–40
Polymorphic epithelial mucin (PEM), 609–10
Polymorphonuclear leukocytes (PMNs)
circulating
inflammatory mediators and, 105–6
transit times in pulmonary circulation, 98–100
Polypeptide GalNAc transferase
salivary mucin biosynthesis and, 553–54
Porcine submaxillary gland mucin, 623
Postischemic tissue injury, 311–24
ischemic preconditioning and, 322–24
leukocytes and, 315–21
mechanisms, 312–24
reactive oxygen metabolites and, 312–15
Potaroo
oxygen consumption rates, 74
Potassium
hyperkalemic periodic paralysis and, 366
Potassium channels
ATP-sensitive
ischemic preconditioning and, 322–23
stretch-activated, 337–38
voltage-gated
S5-S6 interhelical loop, 358
PPHN
See Persistent pulmonary hypertension of newborn
Prazosin
aortic fibronectin mRNA expression and, 814–15
Pregnancy
activin and, 227–29
Prevention of Events with ACE (PEACE), 820
Prostacyclin
cyclooxygenases and, 690
fetal pulmonary circulation and, 120
hypoxic coronary vasodilation and, 775
mucin secretion and, 595
Prostaglandins
cAMP content in glomeruli and, 252
cyclooxygenases and, 690
gastric mucosal hydrophobicity and, 577–78
glomerulopathies and, 251–52
hypoxic coronary vasodilation and, 775
mucin secretion and, 595
pulmonary vascular resistance and, 124
Protein(s)
function
temperature adaptation and, 48–50
sensitivity to temperature, 45–46
structural stability
temperature adaptation and, 46–48
upper thermal limits, 61–62
Protein kinase
cyclic GMP-dependent, 688–89
Protein kinase A
cardiac chloride channel and, 390
neuronal nicotinic acetylcholine receptor and, 539
Protein kinase C
cardiac chloride channel and, 393
endothelin-1 gene activation and, 173
mucin secretion and, 598–99
nicotinic acetylcholine receptor and, 485, 539
Protein-temperature interactions, 43–62
Protein tyrosine kinase (PTK)
NMDA receptor activation and, 507
Proteinuria
glomerular disease and, 249–51
Proteoglycans
synthesis
xanthine-xanthine oxidase and, 250

transforming growth factor-β and, 281
Proximal tubule
sodium transport, 8–9
stretch-activated cation channels, 334
*Pseudomonas aeruginosa*
salivary mucins and, 558
PTK
See Protein tyrosine kinase
Pulmonary airway tone
chemical regulation, 151–65
cysteinyl leukotrienes and, 151–56
neuropeptides and, 156–61
nitrogen oxides and, 161–65
Pulmonary cells
nitric oxide synthases, 162
Pulmonary circulation
changes at birth, 122–27
leukocyte traffic, 97–100
neutrophil migration and, 107
perinatal, 115–31
Pulmonary hypertension
persistent of newborn, 115, 129–31
Pulmonary microvessels
leukocyte margination, 102
Pulmonary surfactant
See Surfactant
Pulmonary vascular resistance
determinants, 117–19
failure to decrease at birth, 129–31
fetal, 115
regulation, 119–22
postnatal
regulation, 127–28
Pulmonary vasculature
morphologic development, 116–17
physiology, 117–31
PUM
See Peanut-lectin binding urinary mucin
Puromycin
progressive glomerular sclerosis and, 273–74
Puromycin aminonucleoside (PAN)
nephrotic syndrome and, 249, 254–55
Pyruvate
hepatic gluconeogensis and, 201
Python
deep body temperatures, 70

R

Radioimmunoassay (RIA), 219
activin, 227
follistatin, 227
inhibin, 222–23
secreted mucin, 593
RAM 7S, 621
Raman spectroscopy
mucin and, 640
*Rana erythraea*
lens crystallins
temperature of 50% loss of structure, 47
*Rana muscosa*
lens crystallins
temperature of 50% loss of structure, 47
Rand, M. J., 659–74
RAS
See Renin-angiotensin system
*Rattus norwegicus*
lens crystallins
temperature of 50% loss of structure, 47
Reactive oxygen metabolites (ROMs), 245–58
ischemia/reperfusion injury and, 312–15
role in glomerular disease, 247–55
sources, 247–49
Recombinant DNA, 219
salivary mucins and, 548
Red blood cells
See Erythrocytes
Reflux nephropathy
glomerular sclerosis and, 272
Renal disease
platelet-derived growth factor and, 302–6
progressive
compensatory growth and, 271–75
mechanisms, 267–71
Renal failure
endothelin and, 175
progressive
angiotensin II and, 285–87
Renal growth
compensatory, 264–67
Renin
regulation of release
nitric oxide and, 778–79
Renin-angiotensin system (RAS), 283–85
cardiac remodeling and, 808–11
losartan and, 269
tissue, 285
Reptation, 647
Reptiles
activity metabolism, 74–75
resting metabolic rates, 73
Reptilian endothermy
evolution, 83–85
Respiration
Cheyne-Stokes, 3
Respiratory burst
chemoattractant receptors and, 837
phagocytosis and, 247
Respiratory water recovery mechanism, 84
Resting metabolic rate
in birds and mammals, 72–73
Resting potentials
ionic theory, 3
Restriction fragment length polymorphism (RFLP)
hyperkalemic periodic paralysis and, 369
Retinal bipolar cells
cyclic GMP-operated channels, 688
Retinal photoreceptor cells
cyclic GMP-operated channels, 687–88
RFLP
See Restriction fragment length polymorphism
Rhodopsin
thermal denaturation, 27
RIA
See Radioimmunoassay
Ribonucleotide reductase
nitric oxide and, 690
Role, L. W., 521–41
ROMs
See Reactive oxygen metabolites
Ross, R., 791–802
Ruben, J., 69–91
*Rutilus rutilus*
sodium pump sites
cold acclimation and, 29

S

*Saccharomyces cerevisiae*
Golgi secretory activity
lipids and, 34
protein thermal stability, 56
Sackin, H., 333–49
Salicylic acid
mucosal phospholipid metabolism/hydrophobicity and, 574
Salivary gland mucin, 622–24
Salivary mucins, 547–60
alimentation and, 555
biosynthesis, 552–55
function, 555–58
oligosaccharides, 551–52
oral flora and, 557–58
as oral therapeutics, 558–60
structure, 548–52
suprastructure, 551
tissue coating and, 555–57
Salt homeostasis
angiotensin II and, 284

*Salvelinus alpinus*
$Na^+/K^+$-ATPase
thermal stability, 28–29
Saralasin
angiotensin II receptor and, 289
Sarcoplasmic reticulum (SR)
calcium release and, 431
Schatzmann, H. J., 1–14
Schulman, H., 417–38
Sebaceous gland antigen (SGA), 610
Second messengers, 417
Secretin
mucin secretion and, 595
Sedimentation equilibrium
mucin and, 640, 643–44
Sedimentation velocity
mucin and, 643–44
Selectins
cobra venom factor and, 108
functions, 833–35
leukocyte-endothelial cell adhesion and, 103–4, 318–19
leukocyte trafficking and, 831
mucin-like glycoproteins and, 607
neutrophil emigration and, 842–44
Selection
protein thermal stability and, 47–48
Septic shock
nitric oxide and, 178–79
Serine proteases
surfactant subtype conversion and, 140, 142
Serotonin
cAMP content in glomeruli and, 252
nitric oxide and, 684, 693
postnatal pulmonary vascular tone and, 128
Serotonin receptor channel, 447–65
activation, 457–59
desensitization, 459–64
distribution and physiological function, 448–49
ion permeation, 452–57
molecular properties, 449–64
Serous acinar cells, 547
SGA
See Sebaceous gland antigen
Shah, S. V., 245–58
Shear stress
endothelin-1 and, 173–74
Shivering thermogenesis, 70
Shock
circulatory
nitric oxide and, 758–59
endotoxic
C-natriuretic peptide and, 181
septic
nitric oxide and, 178–79
Shore, S. A., 151–65
Sialic acids
salivary mucin biosynthesis and, 553
Sialyl Lewis X antigen, 104
Sickle cell anemia
glomerular sclerosis and, 272
Signaling proteins
platelet-derived growth factor and, 298–99
Signal transduction
cardiac chloride channel and, 390–92
mucin secretion and, 597–99
nitric oxide and, 686–91, 749–52
Simian sarcoma virus (SSV)
transforming protein, 298
Simvastatin
platelet-derived growth factor and, 299
SITS
cardiac chloride channel and, 404
Skeletal muscle
active metabolic rate and, 78
calcium/calmodulin-dependent protein kinase, 427
glucose phosphorylation
hexokinase II and, 194
ischemia/reperfusion injury
leukocytes and, 315
mitochondrial fat oxidation, 79
periodic paralysis, 365–67
sodium channel genes
chromosomal localization, 362–63
sodium channels, 356–63
functional expression, 358–61
structure-function correlations, 361–62
Skin homing lymphocytes, 855
Sliding filaments, 3
Small intestine
ischemia/reperfusion injury
leukocytes and, 315
mucin secretion, 594
Smooth muscle
atherosclerotic lesions and, 795–97
Smooth muscle cells
nitric oxide synthases, 162
stretch-activated cation channels, 334
Snakes
deep body temperatures, 70
oxygen consumption rates, 74
SOD
See Superoxide dismutase
Sodium
extracellular
cardiac chloride channel and, 405–6
Sodium channel(s)
muscle disease and, 363–68
skeletal muscle, 356–63
functional expression, 358–61
structure-function correlations, 361–62
Sodium channel disorders, 355–56
molecular pathology, 368–79
Sodium channel genes
chromosomal localization, 362–63
Sodium channel mutations
identification, 370–73
Sodium channel myotonia, 367–68
physiologic studies, 369
Sodium-potassium pump
cardiac glycosides and, 6–8
mineralocorticoids and, 6–7
ouabain and, 7
Sodium pump
action potential generation and, 79
cellular uptake of organic molecules and, 79
lipase and, 10
Sodium transport
proximal tubule, 8–9
Soifer, S. J., 115–31
Somero, G. N., 43–62
Spectroscopy
mucin and, 644–45
*Sphyraena ensis*
cytosolic malate dehydrogenase isoforms
thermal stability, 54
*Sphyraena idiastes*
protein stability and kinetics, 55
*Sphyraena lucasana*
protein stability and kinetics, 55
Spicer, A. P., 607–27
Springer, T. A., 827–60
SR
See Sarcoplasmic reticulum
SSV
See Simian sarcoma virus
Stanley, E., 635–53
Static light scattering
mucin and, 641–42
Stenotherms
thermal sensitivity of proteins, 51–52

Steroid hormones
gene expression and, 6
Stilbenes
cardiac chloride channel and, 404
Stomach
acid environment
gastric mucus and, 648
autodigestion and, 565
ischemia/reperfusion injury
leukocytes and, 315
mucin secretion, 594
*Streptococcus oralis*
salivary mucins and, 558
*Streptococcus pneumoniae*
response of neutrophils, 106–9
*Streptococcus sanguis*
salivary mucins and, 558
Stretch-activated anion channels, 338–39
Stretch-activated cation channels, 334–37
Stretch-activated channels, 333–49
cellular currents and, 347–49
functional classification, 334–40
properties, 340–42
Stretch-activated nonselective channels, 339–40
Stretch-activated potassium channels, 337–38
Stretch activation
mechanics, 340–47
Stretch-inactivated channels, 339–40
Stretch receptor
mechanosensitive channels, 333
Stroke
lesions of atherosclerosis and, 791
Strombine
protein thermal stability, 56
Strophanthoside, 7
Studies of Left Ventricular Dysfunction (SOLVD), 819
Stuehr, D. J., 707–30
Sublingual glands
mucus acinar cells, 547
Submandibular glands
mucin secretion, 594
mucus acinar cells, 547
Submucous plexus
serotonin receptor activation and, 448–49
Substance P
mast cell degranulation and, 160
mucin secretion and, 595
pulmonary C-fibers and, 157
Succinate-ubiquinone oxidoreductase
nitric oxide and, 690, 752
Sucralfate
gastroprotective mechanisms, 578
Sulfonylureas
cardiac chloride channel and, 405
Superior cervical ganglion
calcium permeability, 453
serotonin receptor activation and, 448–49
Superoxide
generation by mesangial cells, 248
glomerular disease and, 255
nitric oxide inactivation and, 666
nitric oxide synthase and, 721–22
reactions with nitric oxide, 746
sequential reduction of oxygen and, 245–46
Superoxide dismutase (SOD)
anti-inflammatory activity, 246
nitric oxide and, 743–44
PAN-induced nephrotic syndrome and, 254–55
Surfactant, 135–48
extracellular
subtypes, 135–37
staining, 572
subtype conversion in vitro, 137–38
requirements, 139–41
Surfactant-associated proteins, 144–46
Surfactant convertase, 135
action and role, 147–48
cellular source, 143–44
identification and purification, 142
physiologic action, 146–47
substrates, 144–46
Survival and Ventricular Enlargement (SAVE) study, 817–18
Survival of Myocardial Infarction Long-term Evaluation (SMILE) study, 818
Synapsin I
calcium/calmodulin-dependent protein kinase and, 429
Synaptic currents
excitatory, 495–512
nicotinic acetylcholine receptor, 470–72
factors controlling, 486–87
NMDA receptor
rising phase, 506
time course, 505–6
non-NMDA receptor
time course, 510–11
Synaptic plasticity
nitric oxide and, 694–99
Synaptic transmission
calcium/calmodulin-dependent protein kinase and, 428–29
neuronal nicotinic acetylcholine receptor and, 537–38
Synaptosomes
calcium/calmodulin-dependent protein kinase, 427–29
*Synechocystis* PCC6803
desaturase mutants
low temperature inhibition of photosynthesis, 29
plasma membrane lipids
isothermal catalytic hydrogenation, 27
Systemic microvessels
leukocyte margination, 102

T

Tabak, L. A., 547–60
Tachykinin(s)
airway responses, 157–60
interactions with leukotrienes, 161
Tachykinin receptor, 157–58
Tannic acid fixation
pulmonary surfactant and, 572
Taurine
protein thermal stability, 56
Taxol
microtubule depolymerization and, 591
Temperature
biogeographical patterning and, 45
lipids in biological membranes and, 19
Temperature-protein interactions, 43–62
Temperature set point
in birds and mammals, 72–73
Tenascin
transforming growth factor-β and, 281
Tenrecs
reptilian-type energetics, 73
Terprenone
gastroprotective mechanisms, 578
Testis
calcium/calmodulin-dependent protein kinase, 427
Tetrahydrobiopterin
nitric oxide synthase and, 725–26
Tetrodotoxin (TTX)
skeletal muscle sodium channels and, 356, 361–62
TGF
See Transforming growth factor

Thalamus
C-natriuretic peptide, 180
Therapsids
near-endothermy, 83
Thermal adaptation
biological membranes and, 19–37
membrane remodeling and, 22–23
paralogous homologues and, 53–54
protein function and, 48–50
protein structural stability and, 46–48
Thermal conductance
in birds and mammals, 72
Thermoconformity, 69–70
Thermogenesis
nonshivering, 70
plasma membranes and, 80
shivering, 70
Thermostatic control center, 73
*Thermus flavus*
malate dehydrogenase
thermal stability, 46
Thiol(s)
reactions with nitric oxide, 747–48
Thiol-containing proteins
nitric oxide and, 750–51
Thomsen's disease, 367
Thrombin
C-natriuretic peptide secretion and, 180
endothelial function and, 831
endothelin-1 and, 182
endothelin-1 gene expression and, 173
P-selectin upregulation and, 104
Thromboxane
glomerulopathies and, 251–52
Thromboxane A2
cyclooxygenases and, 690
fetal pulmonary vascular resistance and, 122
Thromboxane synthetase
nitric oxide and, 749
Thylakoid membranes
chlorophyll
thermal denaturation, 27
homeoviscous adaptation and, 25
Thyroxin
metabolic sensitivity in mammals, 80
Tissue coating
salivary mucins and, 555–57
Tissue injury
reduced oxygen metabolites and, 245
T lymphocytes
atherosclerotic lesions and, 798–99
TNF
See Tumor necrosis factor
Tolbutamide
cardiac chloride channel and, 405
Tooth mineral
salivary mucins and, 556–57
*Torpedo* electric organ
acetylcholine receptor, 475–76
Torpor, 73
Toxic tissue injury
reduced oxygen metabolites and, 245
Trachea
mucin secretion, 594
Tracheobronchial mucins, 619–21
Transcription
nitric oxide and, 751–52
Transcription factors
calcium/calmodulin-dependent protein kinase and, 436–37
Transforming growth factor (TGF)
acute inflammatory response and, 103
C-natriuretic peptide secretion and, 180
Transforming growth factor-β (TGF-β)
angiotensin II and, 287–90
biology, 280
endothelium and, 795
expression in kidney disease, 281–83
fibrogenesis and, 280–81
receptors, 235–36
smooth muscle cells and, 796
Trapidil
platelet-derived growth factor and, 299
*Trematomus centronotus*
thermal sensitivity of proteins, 51–52
*Tropidurus hispidus*
lens crystallins
temperature of 50% loss of structure, 47
Trypsin
light emission from glomeruli and, 248
surfactant subtype conversion and, 141
TTX
See Tetrodotoxin
Tubular myelin, 136
Tumor necrosis factor (TNF)
C-natriuretic peptide secretion and, 180
endothelial adhesiveness and, 830
leukocyte migration and, 102
nitric oxide synthase and, 739–40
reactive oxygen metabolites and, 254
Tumor necrosis factor-α (TNF-α)
matrix protein synthesis and, 281
Turtles
oxygen consumption, 73
*Tyrannosaurus rex*
core body temperature, 88
Tyrosine hydroxylase
calcium/calmodulin-dependent protein kinase and, 428

U

UDP-GalNAc
salivary mucin biosynthesis and, 553–54
Ulcerative colitis, 597
goblet cells and, 587–88
Ulcerogenic agents
gastrointestinal mucosal hydrophobicity and, 574–76
lipid metabolism and, 574–76
Umans, J. G., 771–84
Urokinase
surfactant subtype conversion and, 141
Uterus
calcium/calmodulin-dependent protein kinase, 427

V

Vagus nerve
serotonin receptor activation and, 448–49
*Varanus komodoensis*
near-homeothermy, 70
Vascular cell adhesion molecules (VCAMs)
atherogenesis and, 794
Vascular endothelial cells
endothelin-1 and, 174–75
Vascular endothelium
mechanosensitive channels, 333
Vascular smooth muscle
calcium/calmodulin-dependent protein kinase and, 433
nitrogen oxides and, 162–63
Vascular smooth muscle cells
natriuretic peptide receptors and, 181
nitric oxide and, 741, 752
platelet-derived growth factor and, 299–301

Vasoactive intestinal polypeptide (VIP)
  mucin secretion and, 595
Vasopressin
  C-natriuretic peptide secretion and, 180
  endothelin-1 gene expression and, 173
  nitric oxide synthase and, 694
VCAMs
  See Vascular cell adhesion molecules
Ventricular remodeling
  myocardial infarction and, 807–8
VIP
  See Vasoactive intestinal polypeptide
Viscosity
  mucus gels/mucin solutions and, 645–46
Von Willebrand factor, 637

W

Wasserman, D. H., 191–212
Weibel-Palade bodies, 104
White blood cells
  See Leukocytes
Wolin, M. S., 737–60
Woodruff, T. K., 219–37
Wound healing
  serine proteases and, 142
  transforming growth factor-β and, 281

X

Xanthine oxidase
  postischemic tissues and, 313
Xanthine-xanthine oxidase
  proteoglycan synthesis and, 250
Xanthine-xanthine oxidase system
  myosin light chain phosphorylation and, 252
*Xenopus* oocytes
  nicotinic acetylcholine receptor subunits, 524–32
  stretch-activated cation channels, 334
Xerostomia
  salivary substitutes and, 559
X-ray spectroscopy
  mucin and, 640

Y

Yakel, J. L., 447–65
Yeast
  Golgi secretory activity
    lipids and, 34
  protein thermal stability, 56

Z

Zaprinast
  nitrergic nerve stimulation and, 667
Zymosan
  oxidative burst and, 247
  superoxide/hydrogen peroxide generation and, 248